Correction to “Combined inhibition of de novo pyrimidine synthesis and ATR promotes ATF4-mediated cell death in TP53-deficient ALL”

• October 5, 2026

Thyroid Cancer: What Are the Latest Advances in Treatment?

Thyroid cancer is usually a highly treatable malignancy with overall five-year survival rates over 98%. Many patients with thyroid cancer go on to live for several decades after their disease is cured. 

• by

• September 29, 2026

• 6 min

Deep learning-based segmentation of peritoneal cancer index regions from CT imaging

• by Pieter C. Gort, Lotte J. S. Fleurkens-Ewals, Lenah D. Kampmeijer, Anna F. van Herwijnen, Marion W. Tops-Welten, Cris H. B. Claessens, Joost Nederend, Ignace H. J. T. De Hingh, Max J. Lahaye, Misha D. P. Luyer, Fons van der Sommen

• September 27, 2026

Spinal ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes with a focus on the pediatric population (Part III of ependymomas across compartments)

• by Anthony M. Price, Nathan S. Fredricks, George Koutsouras, Frederic A. Vallejo, Christopher Bonfield, Devang J. Pastakia, Leo Y. Luo, Frederick Boop, Vijay Ramaswamy, Michael C. Dewan

• October 6, 2026